Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
In conventional clinical use, cytosine arabinoside (ara-C) is rapidly deaminated by pyrimidine nucleoside deaminase to the nontoxic compound uracil arabinoside. Tetrahydrouridine (THU) effectively inhibits this enzymatic degradation but is by itself nontoxic. This study demonstrates that concomitant administration of THU markedly increases the myelosuppressive potency of ara-C. When 25 or 50 mg/kg of THU iv and 0.1--0.2 mg/kg of ara-C iv are given daily x 5 days, they produce moderate-to-severe leukopenia and mild-to-moderate thrombocytopenia. A dose of 25 mg/kg of THU with 0.1 mg/kg of ara-C iv daily x 5 days appears appropriate for phase II studies; it produces myelosuppression equivalent to that produced by 3 mg/kg/day x 5 days of ara-C alone. No toxicity occurred with this combination that would not have been expected from ara-C given alone in an equitoxic dose. Although THU and ara-C produced a reduction in peripheral blood and bone marrow blast cells in eight of nine patients with acute leukemia, bone marrow remission did not occur in any of these heavily pretreated patients.
D001853:Bone Marrow / Q000187:drug effects; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage* / Q000378:metabolism; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009700:Nucleoside Deaminases / Q000378:metabolism; D011741:Pyrimidine Nucleosides; D013767:Tetrahydrouridine / Q000008:administration & dosage*; D014529:Uridine / Q000031:analogs & derivatives*
D011741:Pyrimidine Nucleosides; D003561:Cytarabine; D013767:Tetrahydrouridine; D009700:Nucleoside Deaminases; D014529:Uridine